AIM
Price
$1.33
Change
-$0.00 (-0.00%)
Updated
Nov 19 closing price
Capitalization
3.68M
Intraday BUY SELL Signals
NEVPF
Price
$0.03
Change
-$0.00 (-0.00%)
Updated
Jan 23 closing price
Capitalization
45.13M
Intraday BUY SELL Signals
Interact to see
Advertisement

AIM vs NEVPF

Header iconAIM vs NEVPF Comparison
Open Charts AIM vs NEVPFBanner chart's image
AIM ImmunoTech
Price$1.33
Change-$0.00 (-0.00%)
Volume$53.59K
Capitalization3.68M
Abliva AB
Price$0.03
Change-$0.00 (-0.00%)
Volume$58.9K
Capitalization45.13M
AIM vs NEVPF Comparison Chart in %
AIM
Daily Signal:
Gain/Loss:
NEVPF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AIM vs. NEVPF commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AIM is a Hold and NEVPF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (AIM: $1.33 vs. NEVPF: $0.03)
Brand notoriety: AIM and NEVPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AIM: 46% vs. NEVPF: 100%
Market capitalization -- AIM: $3.68M vs. NEVPF: $45.13M
AIM [@Biotechnology] is valued at $3.68M. NEVPF’s [@Biotechnology] market capitalization is $45.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AIM’s FA Score shows that 1 FA rating(s) are green whileNEVPF’s FA Score has 0 green FA rating(s).

  • AIM’s FA Score: 1 green, 4 red.
  • NEVPF’s FA Score: 0 green, 5 red.
According to our system of comparison, both AIM and NEVPF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AIM’s TA Score shows that 4 TA indicator(s) are bullish while NEVPF’s TA Score has 1 bullish TA indicator(s).

  • AIM’s TA Score: 4 bullish, 5 bearish.
  • NEVPF’s TA Score: 1 bullish, 0 bearish.
According to our system of comparison, NEVPF is a better buy in the short-term than AIM.

Price Growth

AIM (@Biotechnology) experienced а -15.82% price change this week, while NEVPF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NEVPF($45.1M) has a higher market cap than AIM($3.68M). NEVPF YTD gains are higher at: -22.222 vs. AIM (-93.283). AIM has higher annual earnings (EBITDA): -15.32M vs. NEVPF (-87.99M). NEVPF has more cash in the bank: 32.7M vs. AIM (835K). AIM has higher revenues than NEVPF: AIM (121K) vs NEVPF (0).
AIMNEVPFAIM / NEVPF
Capitalization3.68M45.1M8%
EBITDA-15.32M-87.99M17%
Gain YTD-93.283-22.222420%
P/E RatioN/AN/A-
Revenue121K0-
Total Cash835K32.7M3%
Total Debt2.81MN/A-
FUNDAMENTALS RATINGS
AIM vs NEVPF: Fundamental Ratings
AIM
NEVPF
OUTLOOK RATING
1..100
7340
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
86
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9740
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a6

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AIM's Valuation (27) in the null industry is somewhat better than the same rating for NEVPF (86). This means that AIM’s stock grew somewhat faster than NEVPF’s over the last 12 months.

AIM's Profit vs Risk Rating (100) in the null industry is in the same range as NEVPF (100). This means that AIM’s stock grew similarly to NEVPF’s over the last 12 months.

NEVPF's SMR Rating (98) in the null industry is in the same range as AIM (100). This means that NEVPF’s stock grew similarly to AIM’s over the last 12 months.

NEVPF's Price Growth Rating (40) in the null industry is somewhat better than the same rating for AIM (97). This means that NEVPF’s stock grew somewhat faster than AIM’s over the last 12 months.

NEVPF's P/E Growth Rating (100) in the null industry is in the same range as AIM (100). This means that NEVPF’s stock grew similarly to AIM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AIMNEVPF
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
N/A
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
13%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
13%
Advances
ODDS (%)
Bullish Trend 9 days ago
77%
N/A
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
N/A
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
86%
N/A
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
AIM
Daily Signal:
Gain/Loss:
NEVPF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DOC17.61-0.08
-0.45%
Healthpeak Properties
AMR160.16-1.32
-0.82%
Alpha Metallurgical Resources
FRPH22.99-0.35
-1.49%
FRP Holdings
RDHL1.04-0.02
-1.89%
Redhill Biopharma Ltd
OKYO2.02-0.11
-5.16%
OKYO Pharma Limited

NEVPF and

Correlation & Price change

A.I.dvisor indicates that over the last year, NEVPF has been closely correlated with MLTX. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NEVPF jumps, then MLTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NEVPF
1D Price
Change %
NEVPF100%
N/A
MLTX - NEVPF
70%
Closely correlated
+1.12%
IMA - NEVPF
66%
Loosely correlated
-4.19%
ATYR - NEVPF
65%
Loosely correlated
-3.27%
CELC - NEVPF
61%
Loosely correlated
+2.87%
INBX - NEVPF
59%
Loosely correlated
+5.86%
More